Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: the Chief who wrote (4048)	4/7/2000 9:50:00 AM
From: Montana Wildhack	Read Replies (1) \| Respond to of 14101

Chief, Two points. 1. I won't let you get away with your daytrading comments. I've read far too many of your posts giving insight into situations and you were one of the first to step forward when I was new and advise me where to get information I wanted. Your comments are always welcome to me. 2. I agree with everything you say about Dimethaid. My post referred to the fact that I was margined to the hilt when DMX did it's run in February. I have a ridiculous number of shares that I'm holding to the end. When DMX breaks $15 on the upside I'll start chasing it again to the next level after that. No one can doubt my confidence in Dimethaid and to be clear I'm so certain of success - I'm passing up a promotion at work and instead am passing autonomy to my excellent team of manangers during this year. I won't be working after next year. I have a 95% confidence factor that DMX will blow my $50 target away on the upside and believe the $100 numbers I'm hearing to be more likely. Good to hear your confidence. It must be strong to bring you into a solid long term position. All the best everyone. I think we're in for a positive day. Wolf

To: the Chief who wrote (4048)	4/7/2000 11:46:00 AM
From: the Chief	Read Replies (1) \| Respond to of 14101

This point should have been added to the original post. DMX has "suffered" thru the trials process preserving capital and shareholder value all the way thru the tedium. In the end we will have a company that takes the "elephant" portion of the revenues from all of its drugs, because of its refusal to bend to "large drug producers early buyin on the cheap". This will ensure a much larger profit margin than would normally be afforded a "small" biomed. I am consistently heartened by other biomeds that are three years away from "stage 3 trials approval" selling for more than DMX. The reason is simple.....on FDA approval this thing will "pop" far beyond the others market capitalization, reaching my $23.00 interim forecast in a flash, with little to NO pullback from that level. Obviously "long" on DMX have a good day the Chief